Springbok Analytics, a leader in AI-driven muscle analytics, announced the close of an oversubscribed $5M Series A funding round. The round was led by Transition Equity Partners, LLC (TEP), with participation from the National Basketball Association, Cartan Capital, Boston Global (AUS) and other strategic investors. This funding supports Springbok’s mission to advance muscle health analysis across human performance, life sciences, and longevity. By moving beyond traditional, manual, and subjective muscle analysis methods, Springbok’s AI technology provides unmatched precision, scalability, and actionable insights from rapid MRI scans.
“The successful completion of our Series A funding is a significant milestone for Springbok Analytics, reflecting our team’s singular focus on establishing the standard of care for muscle health and the growing recognition of our technology’s potential,” said Springbok Analytics CEO and Co-Founder Scott Magargee. “This investment will enable us to advance our mission to improve muscle health analysis and expand our impact across clinical care, research, and health. We are excited for this next chapter and remain committed to delivering innovative solutions that empower patients, providers, and researchers in the attainment of precision medicine.”
Springbok Analytics has developed a first-of-its-kind, FDA-cleared AI technology that delivers automated, precise and comprehensive muscle health assessments from MRI scans. Built on more than 15 years of scientific research and validation, the company’s patented technology analyzes muscle and skeletal structures with exceptional accuracy, providing detailed 3D visualizations and critical metrics, including muscle volume, composition, and fat infiltration.
Also Read: Osmind Appoints Dr. William Sauvé as Chief Medical Officer
“Our Series A funding will allow us to expand our reach and continue driving innovation,” said Silvia Blemker, Co-Founder and Chief Scientific Officer of Springbok Analytics. “I’m incredibly proud of our progress and excited about the opportunities ahead to advance muscle research, improve patient outcomes, and empower human performance.”
“Transition Equity Partners is proud to be a strong and early supporter of Springbok Analytics, having led the company’s seed round, and now strengthening the partnership in leading this Series A round,” said Pat Eilers, Managing Partner & Founder of TEP. “Among other achievements, the recent FDA clearance is a key one that highlights the value of Springbok’s technology, accelerates future product development and opens up exciting commercial opportunities in healthcare, including visibility to reimbursement, that benefit athletes at every level and as importantly the health and wellness of the general public as well.”
“Springbok Analytics represents exactly the kind of visionary company that Cartan Capital is proud to support,” said CiCi Bellis, Founder and Managing Partner of Cartan Capital. “Their innovative approach to muscle health analytics addresses critical needs in precision medicine and performance optimization. We’re thrilled to back a company with a proven track record and a clear vision for global impact.”
SOURCE: PRNewswire